Logo image
Back
Determining When to Add Nonstatin Therapy: A Quantitative Approach
Journal article   Open access   Peer reviewed

Determining When to Add Nonstatin Therapy: A Quantitative Approach

Jennifer G Robinson, Roeland Huijgen, Kausik Ray, Jane Persons, John J P Kastelein and Michael J Pencina
Journal of the American College of Cardiology, Vol.68(22), pp.2412-2421
12/06/2016
DOI: 10.1016/j.jacc.2016.09.928
PMID: 27908345
url
https://doi.org/10.1016/j.jacc.2016.09.928View
Published (Version of record) Open Access

Related content

Has comment

Abstract

Costs and uncertainty about the benefits of nonstatin therapies limit their use. The authors sought to identify patients who might benefit from the addition of a nonstatin to background statin therapy. We performed systematic reviews of subgroup analyses from randomized trials and observational studies with statin-treated participants to determine estimated 10-year absolute risk of atherosclerotic cardiovascular disease (ASCVD) and to define high-risk and very high-risk patients. We used the relative risk reductions for the addition of a nonstatin to lower low-density lipoprotein (LDL-C) used to determine the number needed to treat (NNT) to prevent 1 ASCVD event over 5 years for each patient group and to allow comparisons with 5-year cost analyses. The 10-year ASCVD risk is at least 30% (very high risk) for statin-treated participants with clinical ASCVD and comorbidities, and 20% to 29% (high risk) for those with ASCVD without comorbidities or who have heterozygous familial hypercholesterolemia. Adding ezetimibe to reduce low-density LDL-C by 20% would provide a 5-year NNT ≤50 for very high-risk patients with LDL-C ≥130 mg/dl or for high-risk patients with LDL-C ≥190 mg/dl, and an NNT ≤30 for very high-risk patients with LDL-C ≥160 mg/dl. Adding a PCSK9 monoclonal antibody to lower LDL-C by at least 50% would provide an NNT ≤50 for very high-risk and high-risk patients with LDL-C ≥70 mg/dl, and an NNT ≤30 for very high-risk and high-risk patients with an LDL-C ≥130 mg/dl. Adding ezetimibe or PCSK9 monoclonal antibodies to maximally tolerated statin therapy may be cost effective in very high-risk and high-risk patients, depending on baseline LDL-C levels.
 Atherosclerosis - economics Anticholesteremic Agents - therapeutic use Atherosclerosis - drug therapy Cost-Benefit Analysis Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Drug Therapy, Combination

Details

Metrics

29 Record Views
111 Times Cited - Web of Science
Logo image